Silea 0,31 Mg/ 3 Ml, 0,63 Mg/ 3 Ml & 1,25 Mg/ 3 Ml Cipla 0,31 mg, 0,63 mg, 1,25 mg Inhalation solution
PDF Leaflet Revision Date: 04 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of reversible airway obstruction in asthma and bronchospasm prevention.
Dosage (summary)
Adults: 0.63 mg/3 mL thrice daily; max 1.25 mg/3 mL if needed.
Special Populations
- Children <6 years
- Renal impairment
Pregnancy & Breastfeeding
Not adequately studied in pregnancy; use with caution. Unknown if excreted in breast milk.
Key Drug Interactions
- Beta-blockers may cause severe bronchospasm
- Caution with diuretics and digoxin
Contraindications
- Hypersensitivity to levalbuterol or ingredients
- Children <6 years
Common side effects
- Dizziness
- Tachycardia
- Headache
- Nervousness
Counselling Points
- Do not exceed recommended dose
- Monitor for worsening asthma
- Use caution in driving or operating machinery
Serious warnings
- Paradoxical bronchospasm may occur
- Risk of cardiovascular effects
- Potential for hypokalaemia
Important Disclaimer
The Silea 0,31 Mg/ 3 Ml, 0,63 Mg/ 3 Ml & 1,25 Mg/ 3 Ml Cipla 0,31 mg, 0,63 mg, 1,25 mg Inhalation solution professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
